4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Specification of osteoblast cell fate by canonical Wnt signaling requires Bmp2

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Enhanced BMP or canonical Wnt (cWnt) signaling are therapeutic strategies employed to enhance bone formation and fracture repair, but the mechanisms each pathway utilizes to specify cell fate of bone-forming osteoblasts remain poorly understood. Among all BMPs expressed in bone, we find that singular deficiency of Bmp2 blocks the ability of cWnt signaling to specify osteoblasts from limb bud or bone marrow progenitors. When exposed to cWnts, Bmp2-deficient cells fail to progress through the Runx2/Osx1 checkpoint and thus do not upregulate multiple genes controlling mineral metabolism in osteoblasts. Cells lacking Bmp2 after induction of Osx1 differentiate normally in response to cWnts, suggesting that pre- Osx1 + osteoprogenitors are an essential source and a target of BMP2. Our analysis furthermore reveals Grainyhead-like 3 (Grhl3) as a transcription factor in the osteoblast gene regulatory network induced during bone development and bone repair, which acts upstream of Osx1 in a BMP2-dependent manner. The Runx2/Osx1 transition therefore receives crucial regulatory inputs from BMP2 that are not compensated for by cWnt signaling, and this is mediated at least in part by induction and activation of Grhl3.

          Abstract

          Summary: Osteoblast specification requires regulatory inputs from BMP2 at the Runx2/Osx1 transition by a mechanism that is not compensated for by canonical Wnt signaling and involves Grhl3.

          Related collections

          Author and article information

          Journal
          Development
          Development
          DEV
          develop
          Development (Cambridge, England)
          The Company of Biologists Ltd
          0950-1991
          1477-9129
          1 December 2016
          1 December 2017
          : 143
          : 23
          : 4352-4367
          Affiliations
          [1 ] Department of Developmental Biology, Harvard School of Dental Medicine , 188 Longwood Avenue, Boston, MA 02115, USA
          [2 ] Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University , 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan
          [3 ] Instituto de Ciência e Tecnologia, Universidade Federal de São Paulo , Rua Talim, 330, São José dos Campos, São Paulo, CEP 12231-280, Brazil
          Author notes
          [* ]Author for correspondence ( Vicki_Rosen@ 123456hsdm.harvard.edu )
          Author information
          http://orcid.org/0000-0002-2111-9313
          http://orcid.org/0000-0002-5153-2176
          http://orcid.org/0000-0002-3004-1220
          http://orcid.org/0000-0002-1324-2741
          http://orcid.org/0000-0002-4029-1055
          Article
          PMC5201040 PMC5201040 5201040 DEV136879
          10.1242/dev.136879
          5201040
          27802170
          ceca8424-ef88-4646-836f-fc4669225cb4
          © 2016. Published by The Company of Biologists Ltd
          History
          : 18 March 2016
          : 7 October 2016
          Funding
          Funded by: National Institute of Arthritis and Musculoskeletal and Skin Diseases, http://dx.doi.org/10.13039/100000069;
          Award ID: R01 AR055904
          Categories
          203
          209
          Stem Cells and Regeneration

          Osx1,Osteoblast,Wnt,BMP,Dlx5,Grhl3,Mouse MLB13 cells,Sp7
          Osx1, Osteoblast, Wnt, BMP, Dlx5, Grhl3, Mouse MLB13 cells, Sp7

          Comments

          Comment on this article